Supernus Pharmaceuticals Inc [SUPN] stock prices are up 4.46% to $51.48 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SUPN shares have gain 9.16% over the last week, with a monthly amount glided 12.65%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Supernus Pharmaceuticals Inc [NASDAQ: SUPN] stock has seen the most recent analyst activity on October 09, 2025, when Piper Sandler upgraded its rating to a Overweight but kept the price target unchanged to $65 for it. Previously, Cantor Fitzgerald upgraded its rating to Overweight on July 30, 2025, and kept the price target unchanged to $42. On February 19, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $36 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $57 on January 06, 2025. Piper Sandler downgraded its rating to a Neutral and reduced its price target to $36 on September 11, 2024.
The stock price of Supernus Pharmaceuticals Inc [SUPN] has been fluctuating between $29.16 and $57.65 over the past year. Currently, Wall Street analysts expect the stock to reach $61 within the next 12 months. Supernus Pharmaceuticals Inc [NASDAQ: SUPN] shares were valued at $51.48 at the most recent close of the market. An investor can expect a potential return of 18.49% based on the average SUPN price forecast.
Analyzing the SUPN fundamentals
The Supernus Pharmaceuticals Inc [NASDAQ:SUPN] reported sales of 681.54M for trailing twelve months, representing a surge of 9.34%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -0.31%, Pretax Profit Margin comes in at -0.3%, and Net Profit Margin reading is -0.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.0, Equity is -0.0 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 48.94 points at the first support level, and at 46.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 53.07, and for the 2nd resistance point, it is at 54.65.
Ratios To Look Out For
It’s worth pointing out that Supernus Pharmaceuticals Inc [NASDAQ:SUPN]’s Current Ratio is 1.80. Also, the Quick Ratio is 1.56, while the Cash Ratio stands at 0.46. Considering the valuation of this stock, the price to sales ratio is 4.33, the price to book ratio is 2.80.
Transactions by insiders
Recent insider trading involved FRANK MOTTOLA, Officer, that happened on Dec 19 ’25 when 20000.0 shares were purchased. Sr. VP of IP, CSO, Bhatt Padmanabh P. completed a deal on Dec 18 ’25 to sell 710.0 shares. Meanwhile, President, CEO Khattar Jack A. sold 59900.0 shares on Oct 09 ’25.
